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Abstract
The shared characteristics of rheumatoid arthritis (RA) and cancer,
particularly their unchecked growth and invasive behaviors, have
been apparent for some time. However, the molecular mechanisms
underlying these similarities are not clear. In a recent issue of
Arthritis Research & Therapy, Abreu and colleagues link a well-
studied oncogene, Ras, with expression of matrix metallo-
proteinase-3 (MMP-3) in RA. Their study correlates expression of
the Ras guanine nucleotide exchange factor RasGRF1 with MMP-3
expression in RA synovium. They elucidate a potential mechanism
of regulation of MMP-3 expression in RA, suggesting a potential
target for RA treatment.
In a recent issue of Arthritis Research & Therapy, Abreu and
colleagues [1] demonstrate that the Ras guanine nucleotide
exchange factor (GEF) RasGRF1 regulates production of
matrix metalloproteinase-3 (MMP-3) (stromelysin) in synovial
cells taken from the joints of patients with rheumatoid arthritis
(RA). The data suggest that overexpression of RasGRF1
activates signal transduction pathways that target the MMP-3
gene, thereby contributing to joint destruction in RA. In
addition to measuring MMP-3 expression, they measured
levels of the interstitial collagenase, MMP-1, and several other
genes involved in RA. Interestingly, production of MMP-1 and
MMP-3 in RA, but not non-RA (osteoarthritis and reactive
arthritis), synovial tissue correlated positively with expression
of RasGRF1 and co-localized in cells expressing RasGRF1.
In addition, locked nucleic acid (LNA)-mediated knockdown
of RasGRF1 abrogated MMP-3 levels but failed to affect
MMP-1, thus demonstrating disparate regulation of these two
MMPs. The study raises several noteworthy issues, some of
which the authors themselves pointed out.
The first is the similarity between the proliferative and invasive
characteristics of both RA synovium and cancer [2]. In the
present study, the parallel between RA and cancer is further
demonstrated by Ras, a classic oncogene, as a signaling
molecule in RA fibroblast-like synoviocytes. The Ras super-
family of small GTPases is perhaps best known for linking
external mitogenic stimuli to internal signal transduction path-
ways, leading to changes in gene expression affecting cell
proliferation and survival. Upstream signaling events activate
GEFs, which mediate the exchange of GDP (on inactive Ras)
for GTP, thus causing a conformational change to an active
state and interaction with downstream effectors. GTP-bound
Ras is inactivated by its intrinsic GTPase capability, which
hydrolyzes GTP to GDP, and is aided by GTPase-activating
proteins that stimulate the GTPase activity [3].
Increases in the expression or activity of Ras proteins or both
are usually associated with transformed cells and thus with
cancer. However, as Abreu and colleagues [1] note, altered
expression of Ras GEFs has been linked to autoimmune
diseases, many of which display increased proliferation and
invasion resembling those seen in tumors. The specific docu-
mentation of altered expression of a molecule usually asso-
ciated with malignant cells once again underscores similarities
between aspects of cancer and non-malignant proliferative
diseases, such as RA [2]. Although these similarities have
been noted for at least 30 years at a phenotypic level [2], we
are now shedding light on their molecular basis (for example,
changes in the expression of tumor suppressor proteins and
oncogenes and the activation of certain mitogen-activated
protein kinase signal transduction pathways) [4,5]. Abreu and
colleagues [1] include the Ras family of proteins, thus
reiterating how the phenotypic transformation of RA synovium
mimics the genotypic transformation of tumor cells [2].
A second concept that the authors [1] emphasize is the
discordant regulation of MMP-1 and MMP-3. Although early
studies suggested that expression of these MMPs was co-
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ordinate, more recent work indicates disparate regulation,
suggesting that these MMPs are the downstream targets of
different signaling pathways [6-8]. Nonetheless, the promo-
ters of these MMPs share many common cis-regulatory
elements that may respond coordinately [6-8]; the present
report of differential regulation sheds new light on the mecha-
nisms regulating MMP-3 expression and opens up the possi-
bility of developing targeted therapies directed at MMP-1 or
MMP-3.
Interestingly, the authors describe ‘spontaneous’ MMP pro-
duction by RA synovial cells. This means that no exogenous
stimulating agent, such as interleukin-1-beta or tumor
necrosis factor-alpha [4-7], was added to the cultures, so that
they appear to ‘spontaneously’ synthesize MMPs. Primary
cultures of RA synovial cells contain a mixture of activated
fibroblasts, macrophages, and lymphoid cells (T cells, B cells,
and neutrophils), all of which produce a cocktail of cytokines
and growth factors capable of increasing MMP production
[4,5], thereby making MMP expression appear ‘spontaneous’.
Regardless of the combination of factors present in their
cultures [1], only MMP-3 expression was significantly modu-
lated by RasGRF1. This finding provides an opening for
future studies to dissect the roles of various factors present in
RA synovium for their ability to differentially regulate MMP-1
versus MMP-3. It will be essential to test combinations of
factors for this differential regulation, emphasizing the
complex interactions of the potpourri of factors present in RA
tissues and their ability to differentially influence synovial cell
behavior.
Finally, there is the implication that the upregulation of MMP-3
in RA synovial tissue contributes to joint destruction [1].
Indeed, a role for MMP-3 in escalating joint degradation has
been described [9]. MMP-3 activates latent MMP-1 [10] and
also degrades non-collagen matrix [6-8]. Furthermore, with a
comparatively promiscuous portfolio of matrix substrates
[6-8], MMP-3 can be considered a substantial player in RA
pathogenesis. The present study supports this role and
suggests several avenues of future investigation to determine
the mechanism governing the differential expression of
MMP-1 and MMP-3 and to elucidate targeted therapies
directed at one MMP versus the other. Interestingly, by
focusing on MMP-3, there may be indirect suppression of the
ability of MMP-1 to destroy the extracellular matrix in RA.
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